MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts

NEW YORK, May 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts
http://www.reportlinker.com/p01190439/MediPoint-Peripheral-Vascular-Stents-for-the-Lower-Extremity---South-America-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment

MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts

Summary

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in South America (Brazil), and evaluates the adoption and opportunities for this technology in this market.

Scope

- An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized South America PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for PVS
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving South America PVS Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in South America PVS market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 24
2.2 Related Reports 24
3 Peripheral Artery Disease 25
3.1 Overview 25
3.2 Anatomy and Physiology 25
3.2.1 Peripheral Arteries of the Lower Extremity 25
3.3 Pathophysiology 27
3.4 Clinical Presentation 28
3.4.1 Symptoms of Peripheral Artery Disease 28
3.4.2 Risk Factors 30
3.4.3 Disease Classification 30
3.4.4 Diagnosis 31
3.5 Clinical Outcomes 33
3.5.1 Treatment Paradigm 33
3.5.2 Treatment Guidelines 33
3.5.3 Treatment Modalities 37
3.5.4 Endovascular Management of PAD 51
3.6 Epidemiology 55
3.6.1 Peripheral Artery Disease 55
3.7 Economic Impact 57
3.7.1 South America (Brazil) 57
4 Competitive Assessment 58
4.1 Overview 58
4.1.1 Peripheral Vascular Stent Market 58
4.2 Products 61
4.2.1 Bare Metal Stents 61
4.2.2 Drug-Eluting Stents 133
4.2.3 Covered Stents 139
4.2.4 Bioabsorbable Stents 149
5 Unmet Needs 152
5.1 Need for Better Clinical Outcomes in Specific Lesions 152
5.1.1 Chronic Total Occlusions 152
5.1.2 Long Lesions 152
5.1.3 Heavily-Calcified and Uncrossable Lesions 153
5.1.4 Bifurcation Lesions 153
5.2 Need to Improve Medical Therapy 153
5.3 Comparative Studies on Exercise Therapy 154
5.4 Addressing Complications of Lower-Extremity Bypass Surgery 154
5.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 155
5.6 Need for Better Revascularization of the Femoropopliteal Artery 155
5.7 Difficulty in Treating the Infrapopliteal Artery 157
5.8 Lack of Clinical Data 157
5.9 Limited Designs of Low-Profile Devices 158
5.10 Addressing Challenges of Peripheral Stenting 159
5.10.1 Risk of Post-Procedural Complications 159
5.10.2 In-Stent Restenosis 159
5.10.3 Stent Fracture 159
5.10.4 Long-Term Vessel Patency 160
5.10.5 Stent Material 161
5.10.6 Stent Deployment and Deliverability 161
5.10.7 Dual Anti-Platelet Therapy 162
5.10.8 Imaging 162
6 Pipeline Products 163
6.1 Overview 163
6.2 Pipeline by Phase of Development 164
6.3 Pipeline Product Profiles – Peripheral Artery Disease 166
6.3.1 Citation Stent 166
6.3.2 MR-Enhanced Stents 167
6.3.3 ArtiStent 168
6.3.4 Hybrid Dynamic Stent 168
6.3.5 Nipro Corporation Peripheral Stent 168
6.3.6 Yukon 168
6.3.7 iCAST 170
6.3.8 Peritoneal-Lined Stents 171
6.3.9 LifeJacket Stent Graft 172
6.3.10 Esprit Bioabsorbable Vascular Scaffold (BVS) 173
6.3.11 Magic Explorer Stent 174
6.3.12 Stanza 175
6.3.13 3D Biotek Bioresorbable Stent 177
6.3.14 Archer Stent 178
6.3.15 ART Stent 179
6.3.16 Amaranth Bioabsorbable Scaffold 179
6.3.17 TephaFLEX Absorbable Peripheral Stent 179
6.3.18 Zorion Medical Stent 180
6.3.19 Summary 180
7 Clinical Trial Analysis 181
7.1 Overview 181
7.2 Trials to Watch 182
7.2.1 Abbott Vascular 182
7.2.2 Atrium Medical Corporation 183
7.2.3 Biotronik 184
7.2.4 480 Biomedical 184
7.2.5 Cook Medical 185
7.2.6 Covidien 186
7.2.7 Flexible Stenting Solutions 186
7.2.8 IDEV Technologies 187
7.2.9 Medtronic 188
7.2.10 Terumo Medical Corporation 189
8 Industry Overview 190
8.1 Procedure Trends 190
8.1.1 Factors Contributing to Rise of Peripheral Interventions 190
8.1.2 South America 190
8.2 Market Access 192
8.2.1 South America 192
8.3 Reimbursement Trends 194
8.3.1 South America 194
8.4 Regulatory Issues/Recalls 195
8.4.1 Regulatory Issues 195
8.4.2 Recalls 195
8.5 Mergers and Acquisitions 196
8.5.1 Abbott Laboratories 196
8.5.2 Atrium Medical Corporation 197
8.5.3 Boston Scientific Corporation 197
8.5.4 Cordis Corporation (Johnson & Johnson) 198
8.5.5 Covidien 198
8.5.6 CR Bard 198
8.5.7 Medtronic 199
8.5.8 Nexeon Stent 199
8.5.9 Terumo Corporation 199
9 Current and Future Players 200
9.1 Overview 200
9.2 Trends in Corporate Strategy 201
9.3 Company Profiles 204
9.3.1 Abbott Vascular 204
9.3.2 Amaranth Medical 206
9.3.3 Arterial Remodeling Technologies 207
9.3.4 Atrium Medical Corporation 209
9.3.5 Bard Peripheral Vascular (C.R. Bard) 211
9.3.6 Biotronik 213
9.3.7 Boston Scientific Corporation 215
9.3.8 3D Biotek 217
9.3.9 480 Biomedical 218
9.3.10 Cook Medical 220
9.3.11 Cordis Corporation (Johnson & Johnson) 222
9.3.12 CorInnova 224
9.3.13 Covidien 226
9.3.14 Cytograft Tissue Engineering 228
9.3.15 Flexible Stenting Solutions 229
9.3.16 IDEV Technologies 231
9.3.17 Kyoto Medical Planning 232
9.3.18 Medtronic 235
9.3.19 Nexeon Stent 237
9.3.20 Nipro Corporation 239
9.3.21 NovoStent Corporation 240
9.3.22 OptiMed 242
9.3.23 PeriTec Biosciences 243
9.3.24 Synergy Flow 245
9.3.25 Tepha 246
9.3.26 Terumo Corporation 248
9.3.27 TissueGen 250
9.3.28 Translumina 252
9.3.29 Vascular Concepts 253
9.3.30 Veryan Medical 255
9.3.31 VueKlar Cardiovascular 256
9.3.32 W.L. Gore & Associates 258
9.3.33 Zorion Medical 260
10 Market Drivers, Opportunities and Barriers 262
10.1 Market Drivers 262
10.1.1 Rising Prevalence of Disease 262
10.1.2 Long-Term Vessel Patency 264
10.1.3 Reducing the Risk of Restenosis 265
10.1.4 Low-Profile Stent System 265
10.1.5 Self-Expanding Nitinol Stents 266
10.1.6 Limb Amputation 267
10.1.7 Cost Considerations 268
10.1.8 Availability of Long-Term Data 268
10.1.9 Avoiding Stent-in-Stent Procedures 269
10.1.10 Reducing the Need for Dual Anti-Platelet Therapy 269
10.1.11 Accurate Stent Placement 269
10.1.12 Expected Launch of Vascular Stent Products in the US 270
10.2 Opportunities 271
10.2.1 Peripheral Stent Market 271
10.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 273
10.2.3 Biodegradable and Bioabsorbable Stents 274
10.2.4 Target High-Risk Patients 274
10.2.5 Launch Vascular Stents in the Japanese Market 275
10.2.6 Emerging Markets 275
10.3 Market Barriers 276
10.3.1 Slow Adoption 276
10.3.2 High Selling Prices 279
10.3.3 Lack of Reimbursement 279
10.3.4 Substitutes 280
11 Country Outlooks and Forecasts 281
11.1 Brazil 281
11.1.1 Overview 281
11.1.2 Market Analysis 281
12 Appendix 283
12.1 Bibliography 283
12.2 Abbreviations 303
12.3 Report Methodology 306
12.3.1 Overview 306
12.3.2 Coverage 306
12.3.3 Secondary Research 306
12.3.4 Forecasting Methodology 307
12.4 Physicians and Specialists Included in this Study 308
12.5 Physician Survey 310
12.6 About the Authors 311
12.6.1 Analysts 311
12.6.2 Global Head of Healthcare 312
12.7 About MediPoint 312
12.8 About GlobalData 312
12.9 Contact Us 313
12.10 Disclaimer 313

List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 29
Table 2: Risk Factors Associated with Peripheral Artery Disease 30
Table 3: Types of Atherosclerotic Lesions 31
Table 4: TASC II Classification of Iliac Artery Lesions 34
Table 5: TASC II Classification of Femoropopliteal Artery Lesions 35
Table 6: TASC II Classification of Infrapopliteal Artery Lesions 36
Table 7: Complications of Peripheral Artery Bypass Surgery 41
Table 8: Drugs Incorporated Into Drug-Eluting Stents 45
Table 9: Types of Lesions Treated Using Atherectomy 47
Table 10: Prevalence of PAD in Population Age ?65 Years in Brazil, millions, 2010-2019 55
Table 11: Direct and Indirect Healthcare Costs 57
Table 12:Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity in Brazil, 2012 59
Table 13: Marketed Bare Metal Stent Products 61
Table 14: Absolute Stent Family Product Portfolio 62
Table 15: Absolute Stent SWOT Analysis, 2013 65
Table 16: Astron Stent Product Portfolio 66
Table 17: Astron Stent SWOT Analysis, 2013 67
Table 18: BioMimics 3D Stent Product Portfolio 68
Table 19: BioMimics 3D Stent SWOT Analysis, 2013 69
Table 20: Complete Stent SE Product Portfolio 69
Table 21: Complete SE Stent SWOT Analysis, 2013 72
Table 22: E-Luminexx Stent Product Portfolio 73
Table 23: E-Luminexx Stent SWOT Analysis, 2013 74
Table 24: Epic Stent Product Portfolio 75
Table 25: Epic Stent SWOT Analysis, 2013 76
Table 26: FlexStent Iliac Stent System Product Portfolio 77
Table 27: FlexStent Iliac Stent System SWOT Analysis, 2013 78
Table 28: LifeStent Vascular Stent System Product Portfolio 79
Table 29: LifeStent Vascular Stent System SWOT Analysis, 2013 82
Table 30: Maris Deep Stent Product Portfolio 83
Table 31: Maris Deep Stent SWOT Analysis, 2013 84
Table 32: Maris Plus Stent Product Portfolio 85
Table 33: Maris Plus Stent SWOT Analysis, 2013 86
Table 34: Misago Stent Product Portfolio 87
Table 35: Misago Stent SWOT Analysis, 2013 89
Table 36: NovoStent Samba Stent System Product Portfolio 90
Table 37: NovoStent Samba Stent System SWOT Analysis, 2013 91
Table 38: Protégé Family of Stents Product Portfolio 92
Table 39: Protégé Family of Stents SWOT Analysis, 2013 94
Table 40: Pulsar 18 Stent Product Portfolio 95
Table 41: Pulsar 18 Stent SWOT Analysis, 2013 96
Table 42: SMART Stent Product Portfolio 97
Table 43: SMART Stent SWOT Analysis, 2013 99
Table 44: Sinus Stent Family Product Portfolio 100
Table 45: Sinus Stent Family SWOT Analysis, 2013 102
Table 46: Supera Veritas Stent Product Portfolio 103
Table 47: Supera Veritas Stent SWOT Analysis, 2013 105
Table 48: Wallstent Product Portfolio 106
Table 49: Wallstent SWOT Analysis, 2013 107
Table 50: Xpert Stent Product Portfolio 108
Table 51: Xpert Stent SWOT Analysis, 2013 110
Table 52: Zilver Stent Product Portfolio 111
Table 53: Zilver Stent SWOT Analysis, 2013 113
Table 54: Assurant Cobalt Stent Product Portfolio 114
Table 55: Assurant Cobalt Stent SWOT Analysis, 2013 116
Table 56: Chromis Deep Stent Product Portfolio 117
Table 57: Chromis Deep Stent SWOT Analysis, 2013 118
Table 58: Dynamic Stent Product Portfolio 119
Table 59: Dynamic Stent SWOT Analysis, 2013 120
Table 60: Express LD Product Portfolio 121
Table 61: Express LD SWOT Analysis, 2013 122
Table 62: IntraStent LD Stent Product Portfolio 123
Table 63: IntraStent LD Stent SWOT Analysis, 2013 124
Table 64: Omnilink Elite Stent Product Portfolio 125
Table 65: Omnilink Elite Stent SWOT Analysis, 2013 126
Table 66: ParaMount Mini GPS Product Portfolio 127
Table 67: ParaMount Mini GPS SWOT Analysis, 2013 127
Table 68: ProStar Stent Product Portfolio 128
Table 69: ProStar Stent SWOT Analysis, 2013 129
Table 70: Scuba Stent Product Portfolio 130
Table 71: Scuba Stent SWOT Analysis, 2013 131
Table 72: Visi-Pro Stent Product Portfolio 132
Table 73: Visi-Pro Stent SWOT Analysis, 2013 133
Table 74: Marketed Drug-Eluting Stent Products 133
Table 75: Xience Prime BTK Stent Product Portfolio 134
Table 76: Xience Prime BTK Stent SWOT Analysis, 2013 135
Table 77: Zilver PTX Stent Product Portfolio 136
Table 78: Zilver PTX Stent SWOT Analysis, 2013 139
Table 79: Marketed Covered Stent Products 139
Table 80: Gore Viabahn Stent Product Portfolio 140
Table 81: Gore Viabahn Stent SWOT Analysis, 2013 144
Table 82: Gore Tigris Stent Product Portfolio 145
Table 83: Gore Tigris Stent SWOT Analysis, 2013 146
Table 84: V12 Covered Stents Product Portfolio 147
Table 85: V12 Covered Stents SWOT Analysis, 2013 149
Table 86: Remedy Stent Product Portfolio 150
Table 87: Remedy Stent SWOT Analysis, 2012 151
Table 88: Peripheral Vascular Stent Product Pipeline 165
Table 89: Citation Stent SWOT Analysis, 2013 166
Table 90: MR-Enhanced Stents SWOT Analysis, 2013 167
Table 91: Yukon Stent SWOT Analysis, 2013 169
Table 92: iCAST Stent SWOT Analysis, 2013 171
Table 93: Peritoneal-Lined Stents SWOT Analysis, 2013 172
Table 94: Esprit BVS SWOT Analysis, 2013 174
Table 95: Magic Explorer Stent SWOT Analysis, 2013 175
Table 96: Stanza Stent SWOT Analysis, 2013 176
Table 97: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 177
Table 98: Archer Stent SWOT Analysis, 2013 178
Table 99: Abbott Vascular Company Profile 204
Table 100: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 205
Table 101: Abbott Vascular SWOT Analysis, 2013 205
Table 102: Amaranth Medical Company Profile 206
Table 103: Amaranth Medical, Pipeline Vascular Stent Product 207
Table 104: Amaranth Medical SWOT Analysis, 2013 207
Table 105: Arterial Remodeling Technologies Company Profile 208
Table 106: Arterial Remodeling Technologies, Pipeline Vascular Stent Product 208
Table 107: Arterial Remodeling Technologies SWOT Analysis, 2013 209
Table 108: Atrium Medical Corporation Company Profile 209
Table 109: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 210
Table 110: Atrium Medical Corporation SWOT Analysis, 2013 211
Table 111: Bard Peripheral Vascular (C.R. Bard) Company Profile 211
Table 112: Bard Peripheral Vascular (C.R. Bard), Marketed Vascular Stent Products 212
Table 113: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 213
Table 114: Biotronik Company Profile 213
Table 115: Biotronik, Marketed and Pipeline Vascular Stent Products 214
Table 116: Biotronik SWOT Analysis, 2013 215
Table 117: Boston Scientific Corporation Company Profile 215
Table 118: Boston Scientific Corporation, Marketed Vascular Stent Products 216
Table 119: Boston Scientific Corporation SWOT Analysis, 2013 216
Table 120: Company Profile – 3D Biotek 217
Table 121: 3D Biotek, Pipeline Vascular Stent Product 218
Table 122: 3D Biotek SWOT Analysis, 2013 218
Table 123: 480 Biomedical Company Profile 219
Table 124: 480 Biomedical, Pipeline Vascular Stent Product 219
Table 125: 480 Biomedical SWOT Analysis, 2013 220
Table 126: Cook Medical Company Profile 220
Table 127: Cook Medical, Marketed Vascular Stent Products 221
Table 128: Cook Medical SWOT Analysis, 2013 222
Table 129: Cordis Corporation Company Profile 222
Table 130: Cordis Corporation, Marketed Vascular Stent Product 223
Table 131: Cordis Corporation SWOT Analysis, 2013 224
Table 132: CorInnova Company Profile 224
Table 133: CorInnova, Pipeline Vascular Stent Product 225
Table 134: CorInnova SWOT Analysis, 2013 225
Table 135: Covidien Company Profile 226
Table 136: Covidien, Marketed Vascular Stent Products 227
Table 137: Covidien SWOT Analysis, 2013 227
Table 138: Company Profile – Cytograft Tissue Engineering 228
Table 139: Cytograft Tissue Engineering, Pipeline Vascular Stent Product 229
Table 140: Cytograft Tissue Engineering SWOT Analysis, 2013 229
Table 141: Flexible Stenting Solutions Company Profile 229
Table 142: Flexible Stenting Solutions, Marketed Vascular Stent Product 230
Table 143: Flexible Stenting Solutions SWOT Analysis, 2013 230
Table 144: IDEV Technologies Company Profile 231
Table 145: IDEV Technologies, Marketed Vascular Stent Product 232
Table 146: IDEV Technologies SWOT Analysis, 2013 232
Table 147: Kyoto Medical Planning Company Profile 233
Table 148: Kyoto Medical Planning, Marketed Vascular Stent Product 234
Table 149: Kyoto Medical Planning SWOT Analysis, 2013 234
Table 150: Medtronic Company Profile 235
Table 151: Medtronic's Marketed Vascular Stent Products 236
Table 152: Medtronic SWOT Analysis, 2013 237
Table 153: Nexeon Stent Company Profile 237
Table 154: Nexeon Stent, Pipeline Vascular Stent Product 238
Table 155: Nexeon Stent SWOT Analysis, 2013 238
Table 156: Nipro Corporation Company Profile 239
Table 157: Nipro Corporation, Pipeline Vascular Stent Product 239
Table 158: Nipro Corporation SWOT Analysis, 2013 240
Table 159: NovoStent Corporation Company Profile 240
Table 160: NovoStent Corporation, Marketed Vascular Stent Product 241
Table 161: NovoStent Corporation SWOT Analysis, 2013 241
Table 162: OptiMed Company Profile 242
Table 163: OptiMed, Marketed Vascular Stent Products 243
Table 164: OptiMed SWOT Analysis, 2013 243
Table 165: Company Profile – PeriTec Biosciences 244
Table 166: PeriTec Biosciences, Pipeline Vascular Stent Product 244
Table 167: PeriTec Biosciences SWOT Analysis, 2013 245
Table 168: Synergy Flow Company Profile 245
Table 169: Synergy Flow, Pipeline Vascular Stent Product 246
Table 170: Synergy Flow SWOT Analysis, 2013 246
Table 171: Tepha Company Profile 247
Table 172: Tepha Medical Device, Pipeline Vascular Stent Product 247
Table 173: Tepha SWOT Analysis, 2013 248
Table 174: Terumo Corporation Company Profile 248
Table 175: Terumo Corporation, Marketed Vascular Stent Products 249
Table 176: Terumo Corporation SWOT Analysis, 2013 250
Table 177: TissueGen Company Profile 250
Table 178: TissueGen, Pipeline Vascular Stent Product 251
Table 179: TissueGen SWOT Analysis, 2013 251
Table 180: Translumina Company Profile 252
Table 181: Translumina, Pipeline Vascular Stent Product 253
Table 182: Translumina SWOT Analysis, 2013 253
Table 183: Vascular Concepts Company Profile 253
Table 184: Vascular Concept, Marketed Vascular Stent Product 254
Table 185: Vascular Concepts SWOT Analysis, 2013 254
Table 186: Company Profile – Veryan Medical 255
Table 187: Veryan Medical, Marketed Vascular Stent Product 256
Table 188: Veryan Medical SWOT Analysis, 2013 256
Table 189: VueKlar Cardiovascular Company Profile 257
Table 190: VueKlar Cardiovascular, Pipeline Vascular Stent Product 257
Table 191: VueKlar Cardiovascular SWOT Analysis, 2013 258
Table 192: W.L. Gore & Associates Company Profile 258
Table 193: W.L. Gore & Associates, Marketed Vascular Stent Products 259
Table 194: W.L. Gore & Associates SWOT Analysis, 2013 259
Table 195: Zorion Medical Company Profile 260
Table 196: Zorion Medical, Pipeline Vascular Stent Product 260
Table 197: Zorion Medical SWOT Analysis, 2013 261
Table 198: Peripheral Vascular Stent Sales ($m) Forecast for Brazil, 2010–2019 281
Table 199: Physicians Surveyed, By Country 310

List of Figures

Figure 1: Peripheral Arteries of the Lower Extremity 26
Figure 2: Pathophysiology of Peripheral Artery Disease 27
Figure 3: Treatment Modalities – Peripheral Artery Disease 37
Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, South America, 2012 (n=5) 38
Figure 5: Treatment of PAD, South America*, 2012 and 2018 (n=5) 40
Figure 6: Types of Stents Used to Treat Peripheral Artery Disease 43
Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease 44
Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease 44
Figure 9: Covered Stents For Treating Peripheral Artery Disease 46
Figure 10: Types of Atherectomy 48
Figure 11: Prevalence of PAD in Population Age ?65 Years in Brazil, millions, 2010–2019 56
Figure 12: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity in Brazil ($), 2012 58
Figure 13: Peripheral Vascular Stent Market ($m) for Each Type of Artery in Brazil, 2012 60
Figure 14: Remedy Stent for Treating Peripheral Artery Disease 150
Figure 15: Pipeline Peripheral Vascular Stent Products, 2013 163
Figure 16: Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 164
Figure 17: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, Brazil, 2010–2019 191
Figure 18: Population (? 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, Brazil, 2010–2019 192
Figure 19: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 200
Figure 20: Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 202
Figure 21: Kyoto Medical Planning, Sales Volume ($m), May 2002–May 2012 233
Figure 22: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 271
Figure 23: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 272
Figure 24: Brazilian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 282

Companies Mentioned
Abbott Vascular
Amaranth Medical
Arterial Remodeling Technologies
Atrium Medical Corporation
Bard Peripheral Vascular (C.R. Bard)
Biotronik
Boston Scientific Corporation
3D Biotek
480 Biomedical
Cook Medical
Cordis Corporation (Johnson & Johnson

To order this report:
Surgical_Equipment Industry: MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker